You are here: Industry Insights > VLA2001

News List

Valneva Announces Positive Booster Data for COVID Vax Candidate contractpharma
December 17, 2021
Valneva SE announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 Vaccine candidate, VLA2001.
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001 AmericanPharmaceuticalReview
December 09, 2021
Valneva SE announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001. This is the second purchase agreement Valneva has secured...
EMA begins rolling review of Valneva’s Covid-19 vaccine candidate VLA2001 Pharmaceutical-Business-Review
December 06, 2021
Valneva stated that it is now focused on securing regulatory approvals for VLA2001 after the positive results from the Phase III trial.
EMA initiates rolling review of Valneva’s COVID-19 vaccine (VLA2001) EuropeanPharmaceuticalReview
December 06, 2021
The European Medicines Agency (EMA)’s human medicines committee (CHMP) has begun a rolling review of VLA2001, a COVID-19 vaccine being developed by Valneva...
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001 AmericanPharmaceuticalReview
December 02, 2021
Valneva a specialty vaccine company, and IDT Biologika announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement that Valneva signed an Advance Purchase Agreement...
Valneva, IDT Biologika partner to produce Covid-19 vaccines Pharmaceutical-Business-Review
December 01, 2021
French company Valneva and IDT Biologika have partnered to manufacture the former’s inactivated vaccine candidate, VLA2001, for Covid-19.
Valneva, IDT Biologika Enter COVID Vax Mfg. Pact ContractPharma
November 30, 2021
Valneva SE, a specialty Vaccine company, and IDT Biologika have entered a collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement...
Valneva Inks APA with European Commission for COVID Vax ContractPharma
November 24, 2021
Valneva SE, a specialty Vaccine company, has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate...
Valneva to supply Covid-19 vaccine doses to EU Pharmaceutical-Business-Review
November 12, 2021
French company Valneva has received European Commission (EC) approval for an agreement to supply the company’s inactivated Covid-19 vaccine candidate, VLA2001.
Further clinical trial planned for Valneva’s COVID-19 vaccine candidate pharmatimes
August 13, 2021
Valneva is planning to initiate a further Phase III trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Previous page 1 2 3 Next page